ALEC ALECTOR

Alector to Participate at Virtual Investor Conferences in September

Alector to Participate at Virtual Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of management will participate in fireside chats at the following upcoming virtual investor conferences:

  • Citi’s 15th Annual BioPharma Virtual Conference, Thursday, September 10, 2020, at 11:40 a.m. ET
  • Morgan Stanley 18th Annual Global Healthcare Conference, Monday, September 14, 2020, at 12:00 p.m. ET

Live webcasts of each fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at . Replays of the webcasts will be available on the Alector website for 30 days following the event.

About Alector

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit 

Contacts

Media:

Erica Jefferson

Vice President, Communications and Public Affairs

Alector, Inc.

301-928-4650

1AB

Dan Budwick

973-271-6085

or

Investors:

Alector, Inc.

EN
03/09/2020

Underlying

ALECALECTOR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALECTOR

 PRESS RELEASE
Free
ALEC ALECTOR

Alector Provides Executive Leadership Update

Alector Provides Executive Leadership Update -- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that its Chief Financial Officer (CFO), Marc Grasso, M.D., will conclude his tenure with the company, effective June 20, 2025, to pursue other opportunities. Neil Berkley, M...

June 13, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Participate in the Goldman Sachs 46th Annual Global Healthc...

Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET. A live webcast of the fireside chat will be available on the “Events & Presentations” page within the In...

June 3, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector Reports First Quarter 2025 Financial Results and Provides Busi...

Alector Reports First Quarter 2025 Financial Results and Provides Business Update Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer’s disease Continuing to pursue Alector Brain Carrier programs, including the company’s anti-amyloid beta antibody and its GCase enzyme replacement therapy Extending runway into the second half of 2027, with $354.6 million in cash, cash equivalents, and investments SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE N...

May 8, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Participate in Upcoming Healthcare Conferences

Alector to Participate in Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 13, 2025, at 2:20 p.m. PT, corporate presentation H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, New...

May 6, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 ...

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollm...

April 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch